Capricor Therapeutics (CAPR) experienced a significant price surge of 5.87% in the intraday trading session on Thursday. This notable movement appears to be driven by a positive analyst report from Oppenheimer.
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Capricor Therapeutics. The analyst's confidence in the company's prospects likely contributed to the stock's soaring price.
While the specific details of the analyst's report are not provided, the reaffirmed Buy rating suggests positive expectations for Capricor Therapeutics' future performance and potential growth opportunities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.